Vitamin D Status and SLE Disease Activity among Dubai Hospital Lupus Patients



Abstract Views
284

Downloads
203

Citations

Share

##plugins.themes.bootstrap3.article.sidebar##

Submitted Jan 24, 2023
Published Mar 12, 2023
10.24018/clinicmed.2023.4.2.251

Abstract viewed = 284 times

Table of Contents

##plugins.themes.bootstrap3.article.main##

Background: Vitamin D deficiency is common worldwide, but is particularly prevalent in the Middle Eastern region, where cultural and religious factors influence its incidence further. As patients with Systemic Lupus Erythematosus (SLE) avoid sun exposure and use medications that could potentially result in vitamin D deficiency, this problem becomes more apparent. Unfortunately, there are no data available on the prevalence of vitamin D deficiency among patients with SLE in our local area.

Objective: To assess the prevalence of vitamin D deficiency among patients with a new onset of systemic lupus erythematosus in Dubai, and to determine whether low vitamin D levels are correlated with disease activity.

Methodology and Data Collection: a retrospective cohort study of patients with new onset of Systemic Lupus Erythematosus, being diagnosed in less than 1 year and were followed up at Dubai Hospital (UAE) from January 2009 till December 2012. Demographic and clinical data were collected as well as 25(OH) D3 levels. The incidence of vitamin D insufficiency was calculated as a ratio between the numbers of patients with 25(OH) D levels below the specified cut-off values (30ng/ml and 10ng/ml, respectively). SLE was diagnosed according to the American college of rheumatology (ACR SLE) classification criteria of 1997. Patients with drug-induced SLE and vitamin D deficiency were excluded.

Results: a total number of 150 patients were included. 87% (n=131) were females and 13% (n=19) were males. The mean vitamin D level at the baseline was 21.6+/- 47 (mean +/- SD), increased to 27.8+/- 16 at 1 year, while the SLEDAI has improved from 8.3+/-5 (mean +/- SD) to 2.4 +/- 2.9 at 1 year respectively. The changes in vitamin D level as well as the SLEDAI were statistically significant with a P value <0.001. Spearman correlation test showed a statistically significant inverse correlation between vitamin D level versus SLEDAI % from baseline to 1-year later.

Conclusion: This study showed a direct inverse relationship between lupus activity and a low level of vitamin D. Furthermore, the SLE disease activity score got better with the improvement in vitamin D level, measured at baseline, and after 12 months period.

Keywords: SLE SLEDAI vitamin D deficiency

References

  1. Litwic AE, Sriranganathan MK, Edwards CJ. Race and the response to therapies for lupus: how strong is the evidence?. International Journal of Clinical Rheumatology. 2013; 8(4): 471.
     Google Scholar
  2. Fatoye F, Gebrye T, Svenson LW. Real-world incidence and prevalence of systemic lupus erythematosus in Alberta, Canada. Rheumatology International. 2018; 38(9): 1721-1726.
     Google Scholar
  3. Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, et al. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta‐analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis & Rheumatology. 2021; 73(6): 991-996.
     Google Scholar
  4. Hart HH, Grigor RR, Caughey DE. Ethnic difference in the prevalence of systemic lupus erythematosus. Annals of the Rheumatic Diseases. 1983; 42(5): 529-532.
     Google Scholar
  5. Siegel M, Lee SL. The epidemiology of systemic lupus erythematosus. Semin Arthritis Rheum. 1973; 3(1): 1-54.
     Google Scholar
  6. Hochberg MC. Racial differences in the descriptive and clinical epidemiology of systemic lupus erythematosus in the United States. In: Proceedings of the Second International Conference on Systemic Lupus Erythematosus, Tokyo, 1989: 32.
     Google Scholar
  7. Jiménez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clinical Reviews in Allergy & Immunology. 2003; 25(1): 3-11.
     Google Scholar
  8. Bongu A, Chang E, Ramsey-Goldman R. Can morbidity and mortality of SLE be improved?. Best Practice & Research Clinical Rheumatology. 2002; 16(2): 313-332.
     Google Scholar
  9. Lazaro D. Elderly-onset systemic lupus erythematosus. Drugs & Aging. 2007; 24(9): 701-715.
     Google Scholar
  10. Amissah-Arthur MB, Gordon C. GPs have key role in shared care of patients with SLE. The Practitioner. 2009; 253(1724): 19-25.
     Google Scholar
  11. Bae SC, Fraser P, Liang MH. The epidemiology of systemic lupus erythematosus in populations of African ancestry: a critical review of the “prevalence gradient hypothesis”. Arthritis & Rheumatism. 1998; 41(12): 2091-2099.
     Google Scholar
  12. Uthman I, Nasr F, Kassak K, Masri AF. Systemic lupus erythematosus in Lebanon. Lupus. 1999; 8(9): 713-715.
     Google Scholar
  13. Tangpricha V. Vitamin D in food and supplements. The American Journal of Clinical Nutrition. 2012; 95(6): 1299-1300.
     Google Scholar
  14. Wacker M, Holick MF. Sunlight and Vitamin D: A global perspective for health. Dermato-endocrinology. 2013; 5(1): 51-108.
     Google Scholar
  15. Calvo MS, Whiting SJ, Barton CN. Vitamin D intake: a global perspective of current status. The Journal of Nutrition. 2005; 135(2): 310-316.
     Google Scholar
  16. Norman AW. From vitamin D to hormone D: fundamentals of the vitamin D endocrine system essential for good health. The American Journal of Clinical Nutrition. 2008; 88(2): 491S-499S.
     Google Scholar
  17. Jones G. Pharmacokinetics of vitamin D toxicity. The American Journal of Clinical Nutrition. 2008; 88(2): 582S-6S.
     Google Scholar
  18. Holick MF. Vitamin D deficiency. New England Journal of Medicine. 2007; 357(3): 266-81.
     Google Scholar
  19. Omdahl JL, Morris HA, May BK. Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annual Review of Nutrition. 2002; 22: 139-166.
     Google Scholar
  20. Mawer EB, Backhouse J, Holman CA, Lumb GA, Stanbury SW. The distribution and storage of vitamin D and its metabolites in human tissues. Clinical Science. 1972; 43(3): 413-31.
     Google Scholar
  21. Vicchio D, Yergey A, O'Brien K, Allen L, Ray R, Holick M. Quantification and kinetics of 25‐hydroxyvitamin D3 by isotope dilution liquid chromatography/thermospray mass spectrometry. Biological Mass Spectrometry. 1993; 22(1): 53-58.
     Google Scholar
  22. Vieth R, ed. The Pharmacology of Vitamin D, Including Fortification Strategies.2nd edn. London: Elsevier, 2005.
     Google Scholar
  23. Garg M, Lubel JS, Sparrow MP, Holt SG, Gibson PR. vitamin D and inflammatory bowel disease–established concepts and future directions. Alimentary Pharmacology & Therapeutics. 2012; 36(4): 324-44.
     Google Scholar
  24. Bikle DD, Schwartz J. Vitamin D binding protein, total and free vitamin D levels in different physiological and pathophysiological conditions. Frontiers In Endocrinology. 2019; 10: 317.
     Google Scholar
  25. Powe CE, Ricciardi C, Berg AH, Erdenesanaa D, Collerone G, Ankers E, et al. Vitamin D–binding protein modifies the vitamin D–bone mineral density relationship. Journal of Bone and Mineral Research. 2011; 26(7): 1609-1616.
     Google Scholar
  26. Holick MF. Deficiency of sunlight and vitamin D. BMJ. 2008; 336(7657): 1318-1319.
     Google Scholar
  27. O'Mahony L, Stepien M, Gibney MJ, Nugent AP, Brennan L. The potential role of vitamin D enhanced foods in improving vitamin D status. Nutrients. 2011; 3(12): 1023-1041.
     Google Scholar
  28. Holick MF, Chen TC. Vitamin D deficiency: a worldwide problem with health consequences. The American Journal of Clinical Nutrition. 2008; 87(4): 1080S-1086S.
     Google Scholar
  29. Holick MF. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. The American Journal of Clinical Nutrition. 2004; 79(3): 362-71.
     Google Scholar
  30. Shoben AB, Kestenbaum B, Levin G, Hoofnagle AN, Psaty BM, Siscovick DS, et al. Seasonal variation in 25-hydroxyvitamin D concentrations in the cardiovascular health study. American Journal of Epidemiology. 2011; 174(12): 1363-1372.
     Google Scholar
  31. Van der Wielen RP, De Groot LC, Van Staveren WA, Löwik MR, Van den Berg H, Haller J, et al. Serum vitamin D concentrations among elderly people in Europe. The Lancet. 1995; 346(8969): 207-10.
     Google Scholar
  32. Clemens TL, Henderson SL, Adams JS, Holick MF. Increased skin pigment reduces the capacity of skin to synthesise vitamin D3. The Lancet. 1982; 319(8263): 74-76.
     Google Scholar
  33. Harris SS, Soteriades E, Coolidge JA, Mudgal S, Dawson-Hughes B. Vitamin D insufficiency and hyperparathyroidism in a low income, multiracial, elderly population. The Journal of Clinical Endocrinology & Metabolism. 2000; 85(11): 4125-4130.
     Google Scholar
  34. Nesby-O'Dell S, Scanlon KS, Cogswell ME, Gillespie C, Hollis BW, Looker AC, et al. Hypovitaminosis D prevalence and determinants among African American and white women of reproductive age: third National Health and Nutrition Examination Survey, 1988–1994. The American Journal of Clinical Nutrition. 2002; 76(1): 187-192.
     Google Scholar
  35. Fuleihan GE, Deeb M. Hypovitaminosis D in a sunny country. New England Journal of Medicine. 1999; 340(23): 1840-1841.
     Google Scholar
  36. Mishal AA. Effects of different dress styles on vitamin D levels in healthy young Jordanian women. Osteoporosis International. 2001; 12(11): 931-935.
     Google Scholar
  37. Arabi A, El Rassi R, El-Hajj Fuleihan G. Hypovitaminosis D in developing countries-prevalence, risk factors and outcomes. Nature Reviews Endocrinology. 2010; 6(10): 550-561.
     Google Scholar
  38. Bikle D. Nonclassic actions of vitamin D. The Journal of Clinical Endocrinology & Metabolism. 2009; 94(1): 26-34.
     Google Scholar
  39. Aranow C. Vitamin D and the immune system. Journal of Investigative Medicine. 2011; 59(6): 881-886.
     Google Scholar
  40. Lemire JM, Adams JS, Sakai R, Jordan SC. 1 alpha, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. The Journal of Clinical Investigation. 1984; 74(2): 657-661.
     Google Scholar
  41. Chen S, Sims GP, Chen XX, Gu YY, Chen S, Lipsky PE. Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. The Journal of Immunology. 2007; 179(3): 1634-1647.
     Google Scholar
  42. Liu PT, Stenger S, Li H, Wenzel L, Tan BH, Krutzik SR, et al. Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science. 2006; 311(5768): 1770-1773.
     Google Scholar
  43. Ginde AA, Mansbach JM, Camargo CA. Association between serum 25-hydroxyvitamin D level and upper respiratory tract infection in the Third National Health and Nutrition Examination Survey. Archives of Internal Medicine. 2009; 169(4): 384-390.
     Google Scholar
  44. Laaksi I, Ruohola JP, Tuohimaa P, Auvinen A, Haataja R, Pihlajamäki H, Ylikomi T. An association of serum vitamin D concentrations< 40 nmol/L with acute respiratory tract infection in young Finnish men. The American Journal of Clinical Nutrition. 2007; 86(3): 714-717.
     Google Scholar
  45. Cannell JJ, Vieth R, Umhau JC, Holick MF, Grant WB, Madronich S, et al. Epidemic influenza and vitamin D. Epidemiology & Infection. 2006; 134(6): 1129-1140.
     Google Scholar
  46. Bodnar LM, Krohn MA, Simhan HN. Maternal vitamin D deficiency is associated with bacterial vaginosis in the first trimester of pregnancy. Journal of Nutrition. 2009;139(6):1157–61.
     Google Scholar
  47. Villamor E. A potential role for vitamin D on HIV infection?. Nutrition Reviews. 2006; 64(5): 226-33.
     Google Scholar
  48. Rodriguez M, Daniels B, Gunawardene S, Robbins GK. High frequency of vitamin D deficiency in ambulatory HIV-positive patients. AIDS Research and Human Retroviruses. 2009; 25(1): 9-14
     Google Scholar
  49. Yamshchikov AV, Desai NS, Blumberg HM, Ziegler TR, Tangpricha V. Vitamin D for Treatment and Prevention of Infectious Diseases; A Systematic Review of Randomized Controlled Trials. Endocrine Practice. 2009; 15(5): 438-449.
     Google Scholar
  50. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H. Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. The American Journal of Clinical Nutrition. 2010; 91(5): 1255-1260
     Google Scholar
  51. Kamen D, Aranow C. Vitamin D in systemic lupus erythematosus. Current opinion in Rheumatology. 2008; 20(5): 532-537.
     Google Scholar
  52. Correale J, Ysrraelit MC, Gaitán MI. Immunomodulatory effects of Vitamin D in multiple sclerosis. Brain. 2009; 132(5): 1146-60.
     Google Scholar
  53. Smolders J, Menheere P, Kessels A, Damoiseaux JG, Hupperts R. Association of vitamin D metabolite levels with relapse rate and disability in multiple sclerosis. Multiple Sclerosis Journal. 2008; 14(9): 1220-1224.
     Google Scholar
  54. Craig SM, Yu F, Curtis JR, Alarcón GS, Conn DL, Jonas B, et al. Vitamin D status and its associations with disease activity and severity in African Americans with recent-onset rheumatoid arthritis. The Journal of Rheumatology. 2010; 37(2): 275-281.
     Google Scholar
  55. Patel S, Farragher T, Berry J, Bunn D, Silman A, Symmons D. Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis & Rheumatism: Official Journal of the American College of Rheumatology. 2007; 56(7): 2143-2149.
     Google Scholar
  56. Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy. 2018; 7(1): 59-85.
     Google Scholar
  57. Sigmundsdottir H, Pan J, Debes GF, Alt C, Habtezion A, Soler D, Butcher EC. DCs metabolize sunlight-induced vitamin D3 to'program'T cell attraction to the epidermal chemokine CCL27. Nature Immunology. 2007; 8(3): 285-93.
     Google Scholar
  58. Heine G, Niesner U, Chang HD, Steinmeyer A, Zügel U, Zuberbier T, et al. 1, 25‐dihydroxyvitamin D3 promotes IL‐10 production in human B cells. European Journal of Immunology. 2008; 38(8): 2210-2218.
     Google Scholar
  59. Bhalla AK, Amento EP, Serog B, Glimcher LH. 1, 25-Dihydroxyvitamin D3 inhibits antigen-induced T cell activation. The Journal of Immunology. 1984; 133(4): 1748-1754.
     Google Scholar
  60. Mattner F, Smiroldo S, Galbiati F, Muller M, Di Lucia P, Poliani PL, et al. Inhibition of Th1 development and treatment of chronic‐relapsing experimental allergic encephalomyelitis by a non‐hypercalcemic analogue of 1, 25‐dihydroxyvitamin D3. European Journal of Immunology. 2000; 30(2): 498-508.
     Google Scholar
  61. Boonstra A, Barrat FJ, Crain C, Heath VL, Savelkoul HF, O’Garra A. 1α, 25-Dihydroxyvitamin D3 has a direct effect on naive CD4+ T cells to enhance the development of Th2 cells. The Journal of Immunology. 2001; 167(9): 4974-4980.
     Google Scholar
  62. Tang J, Zhou RU, Luger D, Zhu W, Silver PB, Grajewski RS, et al. Calcitriol suppresses antiretinal autoimmunity through inhibitory effects on the Th17 effector response. The Journal of Immunology. 2009; 182(8): 4624-4632.
     Google Scholar
  63. Daniel C, Sartory NA, Zahn N, Radeke HH, Stein JM. Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th17 to a Th2 and regulatory T cell profile. Journal of Pharmacology and Experimental Therapeutics. 2008; 324(1): 23-33.
     Google Scholar
  64. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1α, 25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. The Journal of Immunology. 2001; 167(4): 1945-1953
     Google Scholar
  65. Barrat FJ, Cua DJ, Boonstra A, Richards DF, Crain C, Savelkoul HF, et al. In vitro generation of interleukin 10–producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)–and Th2-inducing cytokines. The Journal of Experimental Medicine. 2002; 195(5): 603-616
     Google Scholar
  66. Gorman S, Kuritzky LA, Judge MA, Dixon KM, McGlade JP, Mason RS, et al. Topically applied 1, 25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+ CD25+ cells in the draining lymph nodes. The Journal of Immunology. 2007; 179(9): 6273-6283.
     Google Scholar
  67. Penna G, Roncari A, Amuchastegui S, Daniel KC, Berti E, Colonna M, et al. Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+ Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood. 2005; 106(10): 3490-3497.
     Google Scholar
  68. Almerighi C, Sinistro A, Cavazza A, Ciaprini C, Rocchi G, Bergamini A. 1α, 25-dihydroxyvitamin D3 inhibits CD40L-induced pro-inflammatory and immunomodulatory activity in human monocytes. Cytokine. 2009; 45(3): 190-197.
     Google Scholar
  69. Piemonti L, Monti P, Sironi M, Fraticelli P, Leone BE, Dal Cin E, Allavena P, Di Carlo V. Vitamin D3 affects differentiation, maturation, and function of human monocyte-derived dendritic cells. The Journal of Immunology. 2000; 164(9): 4443-4451.
     Google Scholar
  70. The Endocrine Society. Endocrine Society Guidelines. [Internet] 2011 [cited 2022 November 11] Available from: drtsoukalas.com
     Google Scholar
  71. Damanhouri LH. Vitamin D deficiency in Saudi patients with systemic lupus erythematosus. Saudi Medical Journal. 2009; 30(10): 1291-1295.
     Google Scholar
  72. Attar SM, Siddiqui AM. Vitamin d deficiency in patients with systemic lupus erythematosus. Oman Medical Journal. 2013; 28(1): 42.
     Google Scholar
  73. Handono K, Puspitasari L, Rudijanto A, Wahono S, Kalim H. Vitamin D serum level and disease activity in patients with systemic lupus erythematosus. International Journal of Pharmaceutical Science Invention. 2013; 2(2): 35-40.
     Google Scholar
  74. Toloza SM, Cole DE, Gladman DD, Ibanez D, Urowitz MB. Vitamin D insufficiency in a large female SLE cohort. Lupus. 2010; 19(1): 13-19.
     Google Scholar
  75. Kim HA, Sung JM, Jeon JY, Yoon JM, Suh CH. Vitamin D may not be a good marker of disease activity in Korean patients with systemic lupus erythematosus. Rheumatology International. 2011; 31(9): 1189-1194.
     Google Scholar
  76. Mouyis M, Ostor AJ, Crisp AJ, Ginawi A, Halsall DJ, Shenker N, et al. Hypovitaminosis D among rheumatology outpatients in clinical practice. Rheumatology. 2008; 47(9): 1348-1351
     Google Scholar
  77. Arnson Y, Amital H, Shoenfeld Y. Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Annals of the Rheumatic Diseases. 2007; 66(9): 1137-1142.
     Google Scholar
  78. Broder AR, Tobin JN, Putterman C. Disease-specific definitions of vitamin D deficiency need to be established in autoimmune and non-autoimmune chronic diseases: a retrospective comparison of three chronic diseases. Arthritis Research & Therapy. 2010; 12(5): 1-8.
     Google Scholar
  79. Mok CC, Birmingham DJ, Leung HW, Hebert LA, Song H, Rovin BH. Vitamin D levels in Chinese patients with systemic lupus erythematosus: relationship with disease activity, vascular risk factors and atherosclerosis. Rheumatology. 2012; 51(4): 644-652.
     Google Scholar
  80. Amital H, Szekanecz Z, Szücs G, Danko K, Nagy E, Csépány T, et al. Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?. Annals of the Rheumatic Diseases. 2010; 69(6): 1155-1157.
     Google Scholar
  81. Borba VZ, Vieira JG, Kasamatsu T, Radominski SC, Sato EI, Lazaretti-Castro M. Vitamin D deficiency in patients with active systemic lupus erythematosus. Osteoporosis International. 2009; 20(3): 427-433.
     Google Scholar
  82. Cutolo M. Vitamin D or hormone D deficiency in autoimmune rheumatic diseases, including undifferentiated connective tissue disease. Arthritis Research & Therapy. 2008; 10(6): 1-2.
     Google Scholar
  83. Reynolds JA, Haque S, Berry JL, Pemberton P, Teh LS, Ho P, et al. 25-Hydroxyvitamin D deficiency is associated with increased aortic stiffness in patients with systemic lupus erythematosus. Rheumatology. 2012; 51(3): 544-551.
     Google Scholar
  84. Al-Kushi AG, Azzeh FS, Header EA, ElSawy NA, Hijazi HH, Jazar AS, et al. Effect of Vitamin D and Calcium Supplementation in Patients with Systemic Lupus Erythematosus. Saudi Journal of Medicine and Medical Sciences. 2018; 6(3): 137-142.
     Google Scholar
  85. Kamen DL. Vitamin D in lupus: new kid on the block?. Bulletin of the NYU Hospital for Joint Diseases. 2010; 68(3): 218
     Google Scholar
  86. Carvalho JF, Blank M, Kiss E, Tarr T, Amital H, Shoenfeld Y. Anti‐vitamin D, vitamin D in SLE: preliminary results. Annals of the New York Academy of Sciences. 2007; 1109(1): 550-557.
     Google Scholar
  87. Antico A, Tampoia M, Tozzoli R, Bizzaro N. Can supplementation with vitamin D reduce the risk or modify the course of autoimmune diseases? A systematic review of the literature. Autoimmunity Reviews. 2012; 12(2): 127-136.
     Google Scholar
  88. Muhairi SJ, Mehairi AE, Khouri AA, Naqbi MM, Maskari FA, Kaabi JA, et al. Vitamin D deficiency among healthy adolescents in al ain, united arab emirates. BMC public Health. 2013; 13(1): 1-7.
     Google Scholar
  89. Abdelgadir E, Bashier A, Kathamuthu R, Bashiri S, Alawadi F. Vitamin D deficiency and insufficiency in patients attending a general hospital in Dubai, United Arab Emirates. Ibnosina Journal of Medicine and Biomedical Sciences. 2014; 6(02): 81-84.
     Google Scholar
  90. Al Anouti F, Thomas J, Abdel-Wareth L, Rajah J, Grant WB, Haq A. Vitamin D deficiency and sun avoidance among university students at Abu Dhabi, United Arab Emirates. Dermato-Endocrinology. 2011; 3(4): 235-239.
     Google Scholar
  91. Statache G, Brown S. Vitamin D in Lupus Patients of Childbearing Age: Are We Doing Enough? Front Reprod Health. 2022; 4: 936810.
     Google Scholar
  92. Al Zarooni AA, Nagelkerke N, Al Marzouqi FI, Al Darmaki SH. Risk factors for vitamin D deficiency in Abu Dhabi Emirati population. PloS One. 2022; 17(2): e0264064.
     Google Scholar


Most read articles by the same author(s)